Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.00% · OPTIONAL
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTAutolus Therapeutics plc's latest supported as-filed period reports revenue of $45.7M, 118.4% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -54.87% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 118.37% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 73.17% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 55.20% · CORE
Level · gp.fundamentals.operating_margin
Raw value -95.95% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 38.4%; Operating cash flow increased 65.6%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 118.4%; Operating margin moved 19663 bp higher; Operating income increased 28.4%.
3 evidence-backed componentsFree-cash-flow proxy changed +67.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
AUTL · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001730463-26-000131SEC ↗10-QAug 11, 2026Period Jun 30, 20260001730463-26-000123SEC ↗8-KAug 11, 2026Period Aug 11, 20260001730463-26-000119SEC ↗8-KAug 3, 2026Period Aug 3, 20260001730463-26-000112SEC ↗8-KAug 3, 2026Period Jul 30, 20260001193125-26-329526SEC ↗4Jul 1, 2026Period Jun 29, 20260001730463-26-000107SEC ↗4Jul 1, 2026Period Jun 29, 20260001730463-26-000105SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 2, 2026Filed Sep 3, 2026 | Piccina CintiaU.S. CCO & Country Gen Manager | Open Market SaleDirect | 6,713 | $2 | $15,682 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Piccina CintiaU.S. CCO & Country Gen Manager | Option ExerciseDirect | 20,000 | $2 | $47,000 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Piccina CintiaU.S. CCO & Country Gen Manager | Option ExerciseDirect | 20,000 | $0 | $0 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 | YOUNG WILLIAM DDirector | Grant Or AwardDirect | 31,667 | $0 | $0 | Form 4 ↗ |
| Jun 29, 2026Filed Jul 1, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 61.06% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 10.06% · OPTIONAL
Operating cash flow changed +65.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +28.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Working capital / assets changed -1600 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed +19663 basis points from the comparable as-filed period.
Cash & equivalents changed +38.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Revenue changed +118.4% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001730463-26-000103| YOUNG WILLIAM DDirector |
| Grant Or AwardDirect |
| 47,500 |
| $0 |
| $0 |
| Form 4 ↗ |